文献速递乳腺技术与安全US

超声介导的纳米载体药物递送在乳腺癌治疗中的创新与展望

Ultrasound-Mediated Nanocarrier-Based Drug Delivery in Breast Cancer Therapy: Innovations and Outlook.
PubMed 文献 · J Ultrasound Med · 2025-11-17

本文综述超声作为外部触发手段增强纳米载体介导的乳腺癌治疗效果,涵盖连续与脉冲超声通过声空化和热疗机制改善穿透、定点激活与时空控制释放;超声响应纳米载体在体外和体内乳腺癌模型中展示出向肿瘤递送更高药物浓度并减少健康组织损伤的前景;临床转化的主要障碍包括超声方案标准化、纳米载体设计优化和监管要求。

要点

  • 超声响应纳米载体在乳腺癌模型中可提高肿瘤内药物浓度并减少健康组织损伤。
  • 连续与脉冲超声通过声空化和热疗机制增强药物穿透与定点释放。
  • 临床转化面临超声方案标准化、纳米载体设计和监管要求等障碍。

核心结论

  • 超声作为强外部触发可增强纳米载体介导的乳腺癌治疗疗效,超声响应纳米载体在体外和体内乳腺癌模型中递送更高药物浓度至肿瘤并减少健康组织损伤,临床实施的主要障碍为超声方案标准化、纳米载体设计优化和监管要求。

研究设计与样本

  • 综述,检索范围与纳入文献未在原文中报告。

临床应用与阅片要点

  • 作者认为超声联合纳米载体系统的双诊断治疗能力可实现新的个性化和图像引导治疗方法。
  • 作者指出其既往研究表明超声引导介导可与磁感应联合形成创新的乳腺癌治疗方法。

局限性

  • 临床实施的主要障碍包括超声方案标准化、纳米载体设计优化和监管要求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Breast cancer continues to be one of the most common cancers affecting women worldwide. Yet, early detection and treatment progress remain limited by drug resistance, systemic toxicity and poor tumor specificity. Targeted therapy solves these limitations by directing therapeutic agents to cancerous tissues while protecting healthy cells. Nanocarrier-based delivery systems have improved drug solubility while extending circulation time and enabling controlled drug release at tumor sites. This review examines the current integration of ultrasound (US) as a strong external trigger which boosts nanocarrier-mediated therapy effectiveness. The application of continuous and pulsed US shows potential to enhance drug delivery by improving penetration and site-specific activation and spatiotemporal control of therapeutic release through acoustic cavitation and hyperthermia mechanisms. The application of US-responsive nanocarriers demonstrates promising outcomes in breast cancer models, both in vitro and in vivo, by delivering higher drug concentrations to tumors while minimizing damage to healthy tissues. The research details the US parameters that affect drug release patterns and therapeutic results. Such systems have been investigated for their dual diagnostic and therapeutic (theranostic) capabilities, which enable new personalized and image-guided treatment methods. Various case studies and preclinical evaluations demonstrate the advantages of integrating US with nanocarrier systems. The main obstacles to clinical implementation involve standardizing US protocols and enhancing nanocarrier designs, and addressing regulatory requirements. Our previous research works demonstrate how US-guided mediation can be combined with magnetic induction to create a revolutionary breast cancer treatment approach.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Sengupta S, Bhattacharjee A, Basu B, et al. Ultrasound-Mediated Nanocarrier-Based Drug Delivery in Breast Cancer Therapy: Innovations and Outlook. J Ultrasound Med. 2025. PMID: 41247034. doi:10.1002/jum.70117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。